CISION PR Newswire
PARAGON: THE OVERPRIME INVITES WARRIORS TO CELEBRATE HALLOWEEN WITH SPOOKY IN-GAME CONTENT AND LIMITED-TIME EVENTS
Netmarble celebrates Halloween in Paragon: The Overprime with new costumes and events.
EZGO Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
EZGO Technologies Ltd. received a notification from Nasdaq for non-compliance with minimum bid price requirements.
Trinity Cyber Expands into Australia to Meet Growing International Demand
Trinity Cyber expands to Australia, opens subsidiary and partners with CyberCX for growth and protection against cyber threats in the region.
Data Revenue continues double-digit growth momentum
Tata Communications announces Q2 FY24 financial results with strong revenue growth. Data business grows 14.4% YoY.
Artprice by Artmarket.com congratulates the artist Tarik Kiswanson, winner of the 2023 Marcel Duchamp Prize, sponsored by ADIAF
Tarik Kiswanson wins the Marcel Duchamp Prize for French contemporary art.
Aon: Record $50bn U.S. Severe Convective Storm Losses Drive Total Natural Catastrophe Toll in 2023
Global insured losses from natural disasters reach $88 billion, with SCS being the main cause.
World's first expo on health and healing! 2023 Sancheong World Traditional Medicine Anti-aging Expo ends with great success
World's first health and healing festival showcases traditional Korean medicine globally.
Phase 1a/1b Study Results of Akeso's PD-1/CTLA-4 Bispecific Antibody Published in Cell Reports Medicine, Highlighting Promising Efficacy in Solid Tumors Refractory/Relapsed to Standard Therapy
Akeso announced the publication of a study on cadonilimab, a bispecific antibody. The study showed favorable safety and efficacy in treating advanced solid tumors. Cadonilimab has been approved for recurrent or metastatic cervical cancer. Akeso is actively developing a diverse pipeline of innovative drugs.
